Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical resea...
Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research
About this item
Full title
Author / Creator
Publisher
United States: Mary Ann Liebert, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Mary Ann Liebert, Inc
Subjects
More information
Scope and Contents
Contents
Copper-64 (T(1/2) = 12.7 hours; beta(+), 0.653 MeV [17.8 %]; beta(-), 0.579 MeV [38.4 %]) has decay characteristics that allow for positron emission tomography (PET) imaging and targeted radiotherapy of cancer. The well-established coordination chemistry of copper allows for its reaction with a wide variety of chelator systems that can potentially...
Alternative Titles
Full title
Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2794299
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2794299
Other Identifiers
ISSN
1084-9785
E-ISSN
1557-8852
DOI
10.1089/cbr.2009.0674
